SCHEMBL13380962

SCHEMBL13380962

C(=N/Nc1nc(Nc2ccccc2)nc(Nc2ccccc2)n1)\c1ccc(/C=N/Nc2nc(Nc3ccccc3)nc(Nc3ccccc3)n2)cc1

nearest known ligand 0.93

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ DDX3X O00571 4/20 0.93
▸ MAPT P10636 4/20 0.82
▸ MEN1 O00255 2/20 0.73
▸ KMT2A Q03164 2/20 0.73
▸ HTT P42858 1/20 0.73
▸ NPSR1 Q6W5P4 1/20 0.73
▸ CA12 O43570 8/20 0.68
▸ CA1 P00915 8/20 0.68
▸ CA2 P00918 8/20 0.68
▸ CA9 Q16790 8/20 0.68
▸ ALDH1A1 P00352 3/20 0.64
▸ MAPK1 P28482 1/20 0.64
▸ SMN1; SMN2 Q16637 1/20 0.64
▸ LMNA P02545 2/20 0.60
▸ HPGD P15428 1/20 0.57
▸ RAB9A P51151 1/20 0.57
▸ NOX1 Q9Y5S8 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13380966 0.97 DDX3X (1.00) DDX3XMAPTMEN1KMT2AHTT
SCHEMBL8908392 0.89 DDX3X (0.85) DDX3XMAPTMEN1KMT2AHTT
SCHEMBL8909166 0.89 DDX3X (0.85) DDX3XMAPTMEN1KMT2AHTT
SCHEMBL11913707 0.85 DDX3X (0.69) DDX3XMAPTMEN1KMT2AHTT
SCHEMBL13380954 0.85 MAPT (1.00) DDX3XMAPTMEN1KMT2AHTT
SCHEMBL8238843 0.81 DDX3X (0.68) DDX3XMAPTMEN1KMT2AHTT
SCHEMBL7689352 0.81 MAPT (0.78) DDX3XMAPTMEN1KMT2AHTT
SCHEMBL7696169 0.80 DDX3X (0.69) DDX3XMAPTMEN1KMT2AHTT
SCHEMBL7696168 0.80 DDX3X (0.69) DDX3XMAPTMEN1KMT2AHTT
SCHEMBL22737807 0.79 MAPT (0.68) DDX3XMAPTMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2010-04-01 — — US disclosed
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY UNIVERSITY OF MARYLAND, BALTIMORE (US) 2010-04-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081661-A1 HEME OXYGENASE INHIBITORS, SCREENING METHODS FOR HEME OXYGENASE INHIBITORS AND METHODS OF USE OF HEME OXYGENASE INHIBITORS FOR ANTIMICROBIAL THERAPY HMOX1, HMOX2, PPOX DDX3X 1391/4885MAPT 3791/4885MEN1 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback